Research and Markets (http://www.researchandmarkets.com/research/wvp9ck/relapsing) has announced the addition of the "Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

The report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. It enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope of the Report:

  • The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products.

Companies Mentioned:

  • AbbVie Inc.
  • Actelion Ltd
  • BIOCAD
  • Cognosci, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Merck KGaA
  • Pfenex Inc.
  • Receptos, Inc.
  • VivaCell Biotechnology Espana S.L.

For more information visit http://www.researchandmarkets.com/research/wvp9ck/relapsing